DHA -docosahexanoic acid; DMEM -Dulbecco's modified eagle's medium; DMSOdimethyl sulfoxide; ECM -extracellular matrix; ELISA -enzyme linked immunosorbent assay: EPA -eicosapentanoic acid; FACS -fluorescence activated cell sorting; FBS -foetal bovine serum; FITC -fluorescein isothiocyanate; IMDM -Iscove's modified Dulbecco's medium; PBS -phosphate buffered saline; PDGF -platelet-derived growth factor; PDGFRplatelet-derived growth factor receptor; PSC -pancreatic stellate cell; PUFApolyunsaturated fatty acid; SDS -sodium dodecyl sulfate; SHP-2 -Src-homology phosphatase-2.
Introduction
The omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), which occur in oily fish such as salmon, mackerel, and tuna, are considered to be very healthy constituents of the human diet. Increasingly they are also employed as medical treatments to alleviate specific conditions. One condition in which potential for beneficial effects is being investigated, is pancreatic cancer. Pancreatic cancer represents 3% of all cancer cases in the UK, and offers a dismal prognosis with a 5-and 10-year survival rate of 3% and 1% respectively. There has been little improvement in survival rates over the last 40 years, with incidence rates closely mirrored by mortality rates [1] .
Whilst surgery provides a potentially curative option for pancreatic cancer [2] , only approximately 15% of cases are suitable for surgical resection, with the majority of patients presenting with advanced disease or overt metastases at the time of diagnosis [3] .
Gemcitabine has long been the mainstay of chemotherapy for pancreatic cancer, with preoperative chemotherapy improving survival in patients with locally advanced disease [4] , and in the palliative setting for those patients with poor performance status [5] . Recent studies have also suggested that combination of therapeutics with gemcitabine, such as nab-paclitaxel [6] , confers a survival advantage when compared to gemcitabine monotherapy in patients with metastatic pancreatic cancer, but may come with a price of increased toxicities.
The incidence of pancreatic cancer has been found to be inversely correlated with intake of PUFAs, including DHA and EPA [7] . Furthermore, administration of EPA and DHA postoperatively, is able to improve pancreas and liver function in patients undergoing surgery for pancreatic/gastrointestinal cancers [8] . However, the greatest potential for clinical utility of PUFAs arises within the palliative setting. A growing number of studies suggest that incorporation of PUFA-enriched supplements into nutritional support regimens for pancreatic cancer patients, may be of clinical benefit without adding to side effect burdens. Cancerrelated cachexia is a major cause of morbidity in pancreatic cancer patients, which may be alleviated by PUFAs such as EPA, resulting in net weight gain and improved quality of life [9, 10] . Importantly, the safety of high dose omega-3 fatty acids is well established, and so may provide an ideal low toxicity adjunct for standard care gemcitabine-based regimens in pancreatic cancer. Establishing mechanisms by which PUFAs contribute to potential anticancer efficacy of chemotherapy over and above cachexia alleviation, have more recently been investigated in patients with advanced pancreatic cancer, by the Dept. Hepatobiliary Surgery, Leicester, UK. Here, patients with locally advanced or metastatic disease underwent standard of care gemcitabine treatment, immediately followed by an intravenous omega-3 fatty acid-rich emulsion (Lipidem™) [11] . Significant decreases in serum platelet-derived growth factor (PDGF) were observed for a proportion of patients in this study, with these responders exhibiting improved overall survival compared to the non-responders. Despite this observation clinically, there is still a paucity of data establishing how such mechanism-based observations may contribute to the combined efficacy of PUFAs and gemcitabine. This is essential if this combination is to gain further credence for clinical utility in the palliative setting. To this end, we investigated the effects of gemcitabine in combination with the EPA/DHA mixture, Lipidem™, to establish anti-proliferative and anti-invasive effects in both 2D and 3D culture systems, with specific interest in the incorporation of pancreatic stellate cells to better model the dense desmoplasia which is a characteristic feature of pancreatic cancer.
Materials
Two human pancreatic cancer cell lines, Capan-1 and Panc-1 were obtained from ATCC (Middlesex, UK). An immortalized pancreatic stellate cell line, RLT-PSC was kindly donated by Dr R. Jesenofsky (University of Heidelberg, Germany). All cell lines tested mycoplasma negative on PCR analysis. Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and gemcitabine were obtained from Sigma-Aldrich, (Dorset, UK) and Lipidem™ (DHA/EPA emulsion) from Bbraun (Melsungen, Germany).
Methods

Culture conditions and routine cell culture
Pancreatic cancer cells and pancreatic stellate cells were cultured as adherent monolayers in sterile tissue culture flasks in a humidified atmosphere at 37°C, 5% CO 2 . The Capan-1 cells 
Proliferation assays
Cells were seeded into 24-well plates at a concentration of 5000 cells per well and allowed to adhere for 24 -48 hours dependant on the cell line. The medium was aspirated and 1 mL of medium containing single reagent or reagent combinations, was added to each well at concentrations ranging from 0 µM to 50 µM for DHA and EPA, and 0 µM to 1 µM for Gemcitabine. Lipidem™ was ready supplied as a suspension and was added at approximate concentrations as per the single agents ie, 10 µM Lipidem™ refers to ~10 µM EPA + 10 µM DHA equivalents. DMSO concentrations were equivocal between all treatments, and did not exceed 0.5%. Cells were then cultured for a further 72, 96, 120 or 144 hours prior to trypsinisation and counting using a Z2 particle counter (Beckman Coulter, Bucks, UK).
Annexin V apoptosis assay
Apoptosis was determined using an Annexin V-FITC Kit (BD Biosciences, NJ, USA). Cells 
Cell cycle analysis
Cells were seeded, treated and harvested as per the annexin V apoptosis assay. Pelleted cells were resuspended in 70% ice-cold ethanol and incubated overnight at 4°C. The samples were then pelleted at 350 x g for 10 minutes, the supernatant discarded, the pellet resuspended in 500 µL PBS and ribonuclease A (10 µg/mL) (Sigma-Aldrich) and incubated overnight at 4°C. Propidium iodide was added to a final concentration of 5 µg/mL, and the cells incubated overnight prior to analysis on a BD FACS Aria II with MODFIT LT software.
3D spheroid basement membrane cell invasion assay
The assay was carried out according to the manufacturer's instructions. In brief, cells (3000/well) were resuspended in 1x spheroid formation extracellular matrix (Cultrex, Maryland, USA), and 50 µL of cell suspension aliquoted in to the Spheroid Formation Plate (Cultrex, Maryland, USA). The plate was centrifuged at 200 x g in a swinging bucket rotor at room temperature, and then incubated at 37°C, 5% CO 2 for 72 hours to promote spheroid formation. The plate was then placed on ice, and 50 µL of invasion matrix added to each well of the spheroid formation plate. The plate was centrifuged at 300 x g at 4°C for 5 minutes in a swinging bucket rotor to eliminate bubbles and to position the spheroid in the centre of the well, prior to placing at 37°C, 5% CO 2 for one hour to allow the invasion matrix to set. After one hour, 100 µL of treatment-containing cell culture media was added to the wells and the plate incubated at 37°C, 5% CO 2 for 8 days. Spheroid images were taken using an inverted microscope and pixel area analysed using Image J software. 750,000 PSCs in a 24 well plate. This gel was incubated at 37°C, 5% CO 2 for 1 hour, then 1 mL of 10% DMEM was added on top of the gels and incubated at 37°C, 5% CO 2 overnight.
On day 2, cell suspensions of 125,000 cancer cells/ well or 625, 000 PSCs / well were mixed together. The gels from day 1 were taken out of the incubator and the media carefully removed prior to adding 1 mL of the cell suspension drop-wise on top of the gel. The gels were then incubated overnight at 37°C, 5% CO2.
Nylon sheets were then pre-coated with 250 µL of 7 volumes of collagen type I, 1 volume of 10X DMEM, 1 volume of filtered FBS and 1 volume of 10% DMEM. The collagen was allowed to polymerise for 30 minutes at 37°C, cross-linked with gluteraldehyde (Sigma-Aldrich) / PBS and left for 1 hour at 4°C. Membranes were washed in PBS (x3) and medium (x1), covered in medium and left at 4°C overnight.
The following day, the submerged organotypics were lifted onto metal grids covered by the coated nylon sheets in 6 well plates and fed from below. The gels were fed every 24-48 hours with treatment-containing media and harvested on day 10. Gels were then formalin fixed and paraffin embedded.
Immunohistochemistry
Organotypic cultures were assessed by immunohistochemistry for ki67, E-cadherin and β-catenin (Dako, Cambs, UK) which was undertaken using the Novolink Polymer Detection as per manufacturer's instructions. Imaging was undertaken using a Hamamatsu digital slide scanner (Hamamatsu Photonics UK, Herts, UK) with digital magnification.
Cytokine analysis
PDGF-BB was determined in cell culture supernatants using the Quantikine ELISA kit ( Sample concentrations were subsequently determined from the standard curve.
Western blot
Cells were seeded at 1x10 6 cells/9 cm dish and left to adhere overnight (or 48 hours for Capan-1 cells). Cells were stimulated with PDGF-BB (100 ng/mL) (Sigma) for time points up to 5 hours prior to harvesting using Roche complete lysis M buffer supplemented with
Phostop phosphatase inhibitor cocktail (Roche, West Sussex, UK). Lysates were analysed by SDS-polyacylamide gel electrophoresis for PDGFR-β, phospho-PDGFRβ, SHP-2, phospho-SHP-2, Akt and phospho-Akt (Cell Signalling Technology, Herts, UK). β-Actin was used as a loading control (Santa Cruz, Heidelberg, Germany). In addition to anti-proliferative activity, it has been proposed that omega-3 FAs may have anti-invasion activity [12] . In order to assess this, two culture systems were utilised: a spheroid-based 3D mono-culture, and an air-interface organotypic co-culture system which combines pancreatic stellate cells with tumour cells.
Results
Effects of Omega
Effects of Omega-3 fatty acids on cell migration alone and in combination with gemcitabine
Capan-1, Panc-1 and RLT-PSC cells all showed invasive capacity in the 3D spheroid monoculture assay (figure 4). All treatments inhibited invasion of Capan-1 cells into the invasion matrix, whereas in Panc-1 and RLT-PSC cells, invasion was inhibited only by the combination of Lipidem™ with gemcitabine. This can be clearly observed by the decrease in branching pseudopodia from each spheroid, but is not reflected in overall spheroid area.
Using the air-interface organotypic co-culture model, it was determined that invasive capacity of Capan-1 but not Panc-1 cells was greatly increased by the presence of pancreatic stellate cells (figure 5a). Addition of Lipidem™ (10 µM) to the Capan-1/RLT-PSC co-culture system resulted in decreased invasion and a decrease in the number and intensity of stained cells for both E-cadherin and β-catenin (figure 5b). Combination of Lipidem™ with gemcitabine did not further enhance this.
In the previous clinical study undertaken using Lipidem™ in combination with gemcitabine [11] treatment-induced changes to cytokine profiles were observed. Here we sought to assess whether this could also be observed within an in vitro setting.
Omega-3 fatty acids alone and in combination with gemcitabine, inhibit PDGF secretion from pancreatic cells
Basal levels of PDGF secretion were highest in Capan-1>Panc-1>RLT-PSC (figure 6a). EPA alone significantly reduced PDGF in Capan-1 compared to DMSO control, with the combination of EPA + gemcitabine and Lipidem™ + gemcitabine being the most efficacious.
The combination of Lipidem™ + gemcitabine also significantly decreased PDGF levels 
Discussion
Previous clinical observations [11] have suggested that the combination of gemcitabine with the combined PUFA emulsion, Lipidem™, enhanced patient quality of life and decreased serum cytokine and growth factor levels, including PDGF, which has a strong association with pro-carcinogenic signalling. Here, we sought to further assess mechanistic consequences of this drug combination in vitro, in both pancreatic cancer cell lines, and a pancreatic stellate cell line. It has previously been shown that PUFAs such as DHA and EPA elicit a dosedependent anti-proliferative effect on a number of pancreatic cancer cell lines, including those that exhibit gemcitabine resistance such as Panc-1 cells (reviewed in [13] ), with proliferation further reduced when gemcitabine was combined with single agent PUFAs [14] .
Mechanisms of anti-proliferative effect were partially ascribed to reduced NFκB DNA binding, accompanied by an increase in apoptosis. EPA was also found to induce apoptosis in Panc-1 cells and reduce (cyclooxygenase) COX-2 expression [15] , with PUFAs inducing G2/M arrest in MIA PaCa2 cell lines mediated by reduced cdc2 expression [16] . We have similarly shown that DHA, EPA and the combination (Lipidem™) are able to decrease proliferation in a dose and time dependant manner, not only in pancreatic cancer cells, but in a pancreatic stellate cell line. Induction of apoptosis and cell cycle arrest did not reach statistical significance in this study, but notably, previous PUFA studies were all undertaken at short time points using very high doses of the single omega-3 fatty acids or gemcitabine.
These studies are, therefore, more difficult to relate to clinically relevant endpoints.
For combination dosing within the study described here, approximate IC 25 s for each drug were utilised for up to 144 hours, to ensure that any additive effects would be observed.
Interestingly, growth inhibition using the combination of Lipidem™ and gemcitabine was significantly more efficacious in RLT-PSC cells compared to gemcitabine alone, reflected in an increase in the G1 phase of the cell cycle. No studies have previously investigated the effect of PUFAs on pancreatic stellate cells, which play a crucial role in the maintenance and therapeutic resistance of pancreatic cancer.
Recently, the bisphosphonate, zolendronic acid, in combination with nab-paclitaxel was found to induce apoptosis and G1 cell cycle arrest in pancreatic stellate cells in vitro and in vivo [17] , suggesting that a shift in focus towards targeting the pancreatic stellate cell could offer an appropriate therapeutic target. Pancreatic stellate cells are known to contribute to secretion of extracellular matrix (ECM) [18] . They exist in a quiescent state, until they are activated by a variety of cytokines and growth factors such as PDGF [19] . Here, we have
shown that both Capan-1 and Panc-1 cell lines produced PDGF, and that tumour cell- Therefore, interfering with the establishment and continued deposition of this desmoplastic tumour microenvironment by targeting PSCs, may represent an important strategy by which to improve patient outcomes [20] . This is further supported by findings that expression of PDGFRβ (a marker of activated PSCs, but not usually expressed in pancreatic tumour cells), in tumour stroma can act as a prognostic marker in pancreatic adenocarcinoma [21] .
Organotypic co-culture models provide a useful tool by which to help further elucidate the role of drug intervention strategies targeting the PSCs. This model, described by
Coleman et al., showed that rendering PSCs quiescent, prevented invasion of pancreatic tumour cells into the culture matrix [22] . Here, we established that all treatments were able to inhibit invasion of Capan-1 cells when cultured in mono-culture. Lipdem™-treated media was able to maintain this reduced invasive capacity, even in the presence PSCs. Several studies have previously investigated a role for the anti-invasive properties of PUFAs. Both DHA and EPA were observed to inhibit PDGF-induced migration of human arterial smooth muscle cells [23] , whilst DHA significantly inhibited migration of breast cancer cells in vitro and prevented metastasis to the bone in vivo [24] . One of the mechanisms by which PUFAs may inhibit invasive processes, is via the downregulation or re-localisation of β-catenin expression. Previous studies have shown that DHA induced degradation of β-catenin in COX-2 overexpressing colorectal tumour cells [25] , and downregulated β-catenin in breast cancer xenografts [26] . In keeping with this, we observed that Lipidem™ decreased total and nuclear β-catenin expression in the Capan-1 organotypic cultures, although
counterintuitively, E-cadherin was concurrently downregulated. Membrane co-localization of β-catenin/E-cadherin is usually associated with maintenance of an epithelial phenotype, with E-cadherin loss, and β-catenin nuclear translocation associated with an invasive phenotype. 
